Aberdeen Group plc Trims Stock Holdings in Twist Bioscience Corporation $TWST

Aberdeen Group plc trimmed its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 3.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 308,116 shares of the company’s stock after selling 12,167 shares during the quarter. Aberdeen Group plc owned approximately 0.50% of Twist Bioscience worth $9,773,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Smartleaf Asset Management LLC raised its holdings in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after buying an additional 442 shares during the period. California State Teachers Retirement System lifted its position in shares of Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares during the last quarter. Knights of Columbus Asset Advisors LLC lifted its position in shares of Twist Bioscience by 2.8% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 23,122 shares of the company’s stock worth $651,000 after purchasing an additional 628 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Twist Bioscience by 3.4% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,485 shares of the company’s stock valued at $553,000 after buying an additional 675 shares during the period. Finally, HighMark Wealth Management LLC boosted its position in Twist Bioscience by 2.5% in the 3rd quarter. HighMark Wealth Management LLC now owns 39,462 shares of the company’s stock valued at $1,110,000 after buying an additional 947 shares during the period.

Twist Bioscience Stock Down 2.1%

Shares of NASDAQ TWST opened at $50.12 on Wednesday. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $3.07 billion, a PE ratio of -39.16 and a beta of 2.20. The stock’s fifty day simple moving average is $47.31 and its two-hundred day simple moving average is $37.75. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $57.88.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. The firm’s revenue was up 16.9% on a year-over-year basis. As a group, analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Guggenheim raised their price objective on Twist Bioscience from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Evercore raised their price objective on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Barclays raised their price objective on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Finally, TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

Insider Buying and Selling

In other news, insider Dennis Cho sold 5,000 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total transaction of $249,650.00. Following the completion of the sale, the insider owned 138,581 shares in the company, valued at approximately $6,919,349.33. This represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 5,001 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total value of $232,946.58. Following the sale, the chief executive officer owned 869,312 shares of the company’s stock, valued at approximately $40,492,552.96. This represents a 0.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 49,190 shares of company stock valued at $2,285,695 over the last three months. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.